Skip to main content
GEST Conferences Main banner
Back

    Ghassan Abou-Alfa, MD, MBA (he/him/his)

    Memorial Sloan Kettering Cancer Center
    Cornell University
    New York, New York, United States

    Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK). Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies and in particular hepatobiliary cancers. Professor Abou-Alfa’s research focuses on incorporating small biological molecules and checkpoint inhibitors into standard cancer therapies. Professor Abou-Alfa also led his group at MSK on the efforts evaluating cabozantinib which was approved by the FDA for HCC indication in 2019. Professor Abou-Alfa h collaboratively and part of a team effort helped with the FDA approval of infigratinib, which was approved by the FDA in 2021, for patients with IHC and FGFR-2 alterations. With his heavy involvement the use of checkpoint inhibitors in the malignancies of interest, Professor Abou-Alfa led the effort of positive outcome dual immunotherapy of durvalumab plus tremelimumab the HIMALAYA study worldwide. This adds to a global effort to be understand the tumor immune microenvironment (TIME) that would help identify the most applicable therapeutics or combination of. He also continues to work on determining the right CAR-T antigens for HCC and FLC, and IHC. Professor Abou-Alfa and team have also worked and were first to report on germline alterations associated with biliary tract cancers.
    Professor Abou-Alfa serves on the steering committee of the NCI AIDS Malignancy Consortium, and also serves on steering committee of the International Affairs Committee of the American Society of Clinical Oncology (ASCO). Professor Abou-Alfa is also the immediate previous President for the International Society of Gastrointestinal Oncology (ISGIO). Professor Abou-Alfa completed his postdoctoral training in internal medicine, medical oncology, and hematology at Yale University, maintains a professorshiop at Cornell Universitry, received his MBA from Columbia University, and is completing his JD from Fordham University. Professor Abou-Alfa also hold an adjunct professorship at the Medical School of Trinity College Dublin, Ireland.

    Disclosure information not submitted.

    Presentation(s):